Table 1.

Univariate (UV) and multivariate (MV) Cox proportional hazard models for recurrence-free and overall survival for all patients with baseline samples (N=96).

Variable	Recurrence-free Survivala				Overall Survival
	UV	MV			UV	MVl
	pval	HR (95%CI)b	pval		pval	HR (95%CI)	pval
Tumor L. Iners c	<0.01 d	5.79 (1.98–16.95)	<0.01		0.02	8.60 (1.77–71.77)	<0.01
Institution
LBJe	–				–
MDACCf	0.29				0.07
Age (years)	0.36				0.41
Race
Asian/Black/Other	–				–
Hispanic	0.16				0.99
White	0.52				0.20
BMIf (kg/m2)	0.84				0.40
Smoking Status
Never	–				–
Former	0.76				0.29
Current	0.43				0.63
Histology
Non-squamousg	–				–
Squamous	0.68				0.12
LVSI
No	–				–
Yes	0.91				0.86
Unknown	0.57				0.79
FIGO 2009 Stage h
II-II	–	–			–
III-IV	0.01	2.49 (1.18–5.25)	0.02		0.27	2.82 (0.93–8.49)	0.07
Grade
Other/Unknown	–				–
1	0.99				0.99
2	0.09				0.22
3	0.83				0.70
HPV Type
HPV 16/18	–				–
Negative/Other	0.19				0.07
Cisplatin Cycles	0.36				0.81
Radiation Dose (Gy)	0.92				0.03
Antibiotic Use i
No	–				–
Yes	0.58				0.08
Nodal Status
Negative	–				–
Positive	0.84				0.99
Tumor Dimension (cm)	0.51				0.44
Gut Diversity j	<0.05	0.03 (5.6E–05 –21.19)	0.30		0.01
Gut Evenness k	0.18				0.03

^aN=33 recurrence events.

^bHazard Ratio and 95% Confidence interval on HR for cox proportional hazard (Cox PH) models.

^cIncreasing relative counts in baseline (pretreatment) tumor swabs.

^dBold font indicates p<0.05 variables included in multivariate Cox PH models.

^eLyndon B. Johnson Hospital, Harris Health System, Houston TX.

^fThe University of Texas M.D. Anderson Cancer Center, Houston TX.

^gAdenocarcinoma and adenosquamous carcinoma.

^hThe International Federation of Gynecology and Obstetrics.

ⁱAntibiotic use within 30 days of baseline swab collection extracted from inpatient and outpatient pharmacy and electronic medical record data, antifungals not included.

^jSimpson gut diversity (continuous).

^kPielou’s evenness metric.

^lOverall survival multivariate model includes only gut diversity due to limited number of events.